Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28097914 | 0.79 | POLB (0.45) | MAPK1POLBATML3MBTL1KMT2A | |
| SCHEMBL17296041 | 0.72 | ALOX5 (0.48) | MAPK1POLBATML3MBTL1KMT2A | |
| SCHEMBL20156062 | 0.71 | GABRA1 (0.49) | MAPK1POLBATML3MBTL1KMT2A | |
| SCHEMBL28943463 | 0.69 | NPC1 (0.42) | MAPK1POLBATML3MBTL1KMT2A | |
| SCHEMBL7795144 | 0.64 | ALDH1A1 (0.50) | POLBL3MBTL1KMT2ALMNA | |
| SCHEMBL3583187 | 0.62 | NPC1 (0.46) | MAPK1KMT2ALMNAMAPTNPC1 | |
| SCHEMBL184 | 0.62 | POLB (1.00) | MAPK1POLBATMKMT2AMAPT | |
| SCHEMBL3672275 | 0.62 | POLB (1.00) | MAPK1POLBATMKMT2AMAPT | |
| SCHEMBL1012471 | 0.62 | POLB (1.00) | MAPK1POLBATMKMT2AMAPT | |
| SCHEMBL23399704 | 0.62 | HTR2A (0.40) | LMNABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210207107-A1 | METHODS AND COMPOSITIONS FOR TREATING INEFFECTIVE ERYTHROPOIESIS | ACCELERON PHARMA INC. | 2021-07-08 | — | — | US | claimed |
| EP-2797620-A1 | METHODS AND COMPOSITIONS FOR TREATING INEFFECTIVE ERYTHROPOIESIS | Acceleron Pharma Inc. (US) | 2014-11-05 | — | — | EP | claimed |
| US-20130243743-A1 | METHODS AND COMPOSITIONS FOR TREATING INEFFECTIVE ERYTHROPOIESIS | ACCELERON PHARMA, INC. (US) | 2013-09-19 | — | — | US | claimed |
| WO-2013059347-A1 | METHODS AND COMPOSITIONS FOR TREATING INEFFECTIVE ERYTHROPOIESIS | ACCELERON PHARMA, INC. (US) | 2013-04-25 | — | — | WO | claimed |
| EP-3922259-B1 | METHODS AND COMPOSITIONS USING GDF15 POLYPEPTIDES FOR INCREASING RED BLOOD CELLS | ACCELERON PHARMA INC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-3226887-B1 | ACTRIIB POLYPEPTIDES FOR USE IN THE TREATMENT SIDEROBLASTIC ANEMIA | ACCELERON PHARMA INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11642394-B2 | Methods and compositions using GDF15 polypeptides for increasing red blood cells | ACCELERON PHARMA INC. (US) | 2023-05-09 | — | — | US | disclosed |
| CN-114699529-A | Methods and compositions for treating ulcers | 阿塞勒隆制药公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20220133853-A1 | METHODS AND COMPOSITIONS FOR TREATING ULCERS | ACCELERON PHARMA INC. | 2022-05-05 | — | — | US | disclosed |
| CN-107135646-B | Methods and compositions for treating ulcers | 阿塞勒隆制药公司 | 2022-03-15 | — | — | CN | disclosed |
| US-11260107-B2 | Methods and compositions for treating ulcers | ACCELERON PHARMA INC. (US) | 2022-03-01 | — | — | US | disclosed |
| EP-3922259-A1 | METHODS AND COMPOSITIONS USING GDF15 POLYPEPTIDES FOR INCREASING RED BLOOD CELLS | Acceleron Pharma Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-2509423-A1 | PROCESSES FOR THE PREPARATION OF DEFERASIROX, AND DEFERASIROX POLYMORPHS | Mapi Pharma Limited (IL) | 2012-10-17 | — | — | EP | disclosed |
| US-20120245361-A1 | PROCESSES FOR THE PREPARATION OF DEFERASIROX, AND DEFERASIROX POLYMORPHS | MAPI PHARMA HK LIMITED (CN) | 2012-09-27 | — | — | US | disclosed |
| EP-2412371-A1 | Compositions comprising iron chelators (deferiprone/deferasirox) for use in the treatment of mucormycosis and other fungal diseases | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2011070560-A1 | PROCESSES FOR THE PREPARATION OF DEFERASIROX, AND DEFERASIROX POLYMORPHS | MAPI PHARMA HK LIMITED (CN) | 2011-06-16 | — | — | WO | disclosed |
| US-20100129434-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCORMYCOSIS AND OTHER FUNGAL DISEASES | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2010-05-27 | — | — | US | disclosed |
| EP-2043636-A2 | (COMBI) COMPOSITIONS FOR THE TREATMENT OF MUCORMYCOSIS COMPRISING IRON CHELATOR AND ANTIFUNGAL AGENT | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008537-A2 | COMBI) COMPOSITIONS FOR THE TREATMENT OF MUCORMYCOSIS. COMPRISING IRON CHELATOR AND ANTIFUNGAL AGENT | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20050063903-A1 | cruciferous-related indole particulary diindolylmethanes, zinc/iron chelator, and optionally one or more of a zinc-binding histone deacetylase inhibitor, gallium or an EGFR antagonist, are administered simultaneously | BIORESPONSE L.L.C. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130243743-A1 | METHODS AND COMPOSITIONS FOR TREATING INEFFECTIVE ERYTHROPOIESIS | EPOR, HBG2, HBG1 | MAPK1 4493/4885POLB 2701/4885ATM 4053/4885 |
| US-20210207107-A1 | METHODS AND COMPOSITIONS FOR TREATING INEFFECTIVE ERYTHROPOIESIS | EPOR, HBG2, HBG1 | MAPK1 4493/4885POLB 2701/4885ATM 4053/4885 |
| US-11642394-B2 | Methods and compositions using GDF15 polypeptides for increasing red blood cells | IL15, HBG1, HBG2 | MAPK1 4380/4885POLB 4632/4885ATM 3319/4885 |
| US-20120245361-A1 | PROCESSES FOR THE PREPARATION OF DEFERASIROX, AND DEFERASIROX POLYMORPHS | HAMP, TFRC, SLC40A1 | MAPK1 4690/4885POLB 4094/4885ATM 3603/4885 |
| US-20050063903-A1 | cruciferous-related indole particulary diindolylmethanes, zinc/iron chelator, and optionally one or more of a zinc-binding histone deacetylase inhibitor, gallium or an EGFR antagonist, are administered simultaneously | EZH2, EGFR, ZKSCAN2 | MAPK1 1550/4885POLB 3059/4885ATM 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.